A small molecule-kinase interaction map for clinical kinase inhibitors

被引：1588

作者：

Fabian, MA ^{[1
]}

Biggs, WH ^{[1
]}

Treiber, DK ^{[1
]}

Atteridge, CE ^{[1
]}

Azimioara, MD ^{[1
]}

Benedetti, MG ^{[1
]}

Carter, TA ^{[1
]}

Ciceri, P ^{[1
]}

Edeen, PT ^{[1
]}

Floyd, M ^{[1
]}

Ford, JM ^{[1
]}

Galvin, M ^{[1
]}

Gerlach, JL ^{[1
]}

Grotzfeld, RM ^{[1
]}

Herrgard, S ^{[1
]}

Insko, DE ^{[1
]}

Insko, MA ^{[1
]}

Lai, AG ^{[1
]}

Lélias, JM ^{[1
]}

Mehta, SA ^{[1
]}

Milanov, ZV ^{[1
]}

Velasco, AM ^{[1
]}

Wodicka, LM ^{[1
]}

Patel, HK ^{[1
]}

Zarrinkar, PP ^{[1
]}

Lockhart, DJ ^{[1
]}

机构：

[1] Ambit Biosci, San Diego, CA 92121 USA

来源：

NATURE BIOTECHNOLOGY | 2005年 / 23卷 / 03期

关键词：

D O I：

10.1038/nbt1068

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Kinase inhibitors show great promise as a new class of therapeutics. Here we describe an efficient way to determine kinase inhibitor specificity by measuring binding of small molecules to the ATP site of kinases. We have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clinical development, against a panel of 119 protein kinases. We find that specificity varies widely and is not strongly correlated with chemical structure or the identity of the intended target. Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LICK. We also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib. Our results represent a systematic small molecule-protein interaction map for clinical compounds across a large number of related proteins.

引用

页码：329 / 336

页数：8

共 47 条

[31]

Nagar B, 2002, CANCER RES, V62, P4236

[32] EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy [J].

Paez, JG ;

Jänne, PA ;

Lee, JC ;

Tracy, S ;

Greulich, H ;

Gabriel, S ;

Herman, P ;

Kaye, FJ ;

Lindeman, N ;

Boggon, TJ ;

Naoki, K ;

Sasaki, H ;

Fujii, Y ;

Eck, MJ ;

Sellers, WR ;

Johnson, BE ;

Meyerson, M .

SCIENCE, 2004, 304 (5676) :1497-1500

[33] EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib [J].

Pao, W ;

Miller, V ;

Zakowski, M ;

Doherty, J ;

Politi, K ;

Sarkaria, I ;

Singh, B ;

Heelan, R ;

Rusch, V ;

Fulton, L ;

Mardis, E ;

Kupfer, D ;

Wilson, R ;

Kris, M ;

Varmus, H .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (36) :13306-13311

[34] Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site [J].

Pargellis, C ;

Tong, L ;

Churchill, L ;

Cirillo, PF ;

Gilmore, T ;

Graham, AG ;

Grob, PM ;

Hickey, ER ;

Moss, N ;

Pav, S ;

Regan, J .

NATURE STRUCTURAL BIOLOGY, 2002, 9 (04) :268-272

[35] Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop [J].

Roumiantsev, S ;

Shah, NP ;

Gorre, ME ;

Nicoll, J ;

Brasher, BB ;

Sawyers, CL ;

Van Etten, RA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (16) :10700-10705

[36]

Rusnak DW, 2001, MOL CANCER THER, V1, P85

[37] Display cloning: functional identification of natural product receptors using cDNA-phage display [J].

Sche, PP ;

McKenzie, KM ;

White, JD ;

Austin, DJ .

CHEMISTRY & BIOLOGY, 1999, 6 (10) :707-716

[38] Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia [J].

Shah, NP ;

Nicoll, JM ;

Nagar, B ;

Gorre, ME ;

Paquette, RL ;

Kuriyan, J ;

Sawyers, CL .

CANCER CELL, 2002, 2 (02) :117-125

[39] Overriding imatinib resistance with a novel ABL kinase inhibitor [J].

Shah, NP ;

Tran, C ;

Lee, FY ;

Chen, P ;

Norris, D ;

Sawyers, CL .

SCIENCE, 2004, 305 (5682) :399-401

[40] A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket [J].

Tong, L ;

Pav, S ;

White, DM ;

Rogers, S ;

Crane, KM ;

Cywin, CL ;

Brown, ML ;

Pargellis, CA .

NATURE STRUCTURAL BIOLOGY, 1997, 4 (04) :311-316

← 1 2 3 4 5 →